Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BI 224436 is an HIV-1 integrase inhibitor with effective antiviral activity that acts through a mechanism that is distinct from that of integrase strand transfer inhibitors (INSTIs). This 3-quinolineacetic acid derivative series was identified using an enzymatic integrase long terminal repeat (LTR) DNA 3′-processing assay. A combination of medicinal chemistry, parallel synthesis, and structure-guided drug design led to the identification of BI 224436 as a candidate for preclinical profiling. It has antiviral 50% effective concentrations (EC 50 s) of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM. BI 224436 also has a low, ∼2.1-fold decrease in antiviral potency in the presence of 50% human serum and, by virtue of a steep dose-response curve slope, exhibits serum-shifted EC 95 values ranging between 22 and 75 nM. Passage of virus in the presence of inhibitor selected for either A128T, A128N, or L102F primary resistance substitutions, all mapping to a conserved allosteric pocket on the catalytic core of integrase. BI 224436 also retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. In drug combination studies performed in cellular antiviral assays, BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition. It exhibited excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow [CL], 0.7%; bioavailability [ F ], 54%), monkey (CL, 23%; F , 82%), and dog (CL, 8%; F , 81%). Based on the excellent biological and pharmacokinetic profile, BI 224436 was advanced into phase 1 clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to ALLINIs maps to the IN CCD dimer interface in the vicinity of the LEDGF/p75 binding site171,173,179,182,188.”
From Structure and function of retroviral integrase (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · cited 2×
“Cytotoxicity resulting in 50% death of cells (CC50) was determined using the tetrazolium salt MTT metabolic assay (32).”
MethodColman (2022) · doi:10.1073/pnas · Cited by 4,370
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Purification and Characterization
(2006) · Biomacromolecules · doi:10.1002/0470080124.ch3 · Cited by 2,309
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 2×
“Since the first proof of principle for the diketo acid integrase inhibitors in 2000, HIV integrase has been intensively studied as a target for drug discovery (8).”
BackgroundMethodRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Shaw, G. M., Hahn, B. H., Arya, S. K., Groopman, J. E., Gallo, R. C., & Wong-Staal, F. (1984) · Science · doi:10.1126/science.6095449 · Cited by 633
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544 · cited 1×
“transformed with Prichard and Shipmann’s MacSynergy II software using the Bliss independence model (38).”
MethodAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Research works printed but not linked: 1
- 31. Schmidt NJ, Emmons RW. 1989. General principles of laboratory diagnostic methods for viral, rickettsial and chlamydial infections, p 1-35. In Schmidt NJ, Emmons RW (ed), Diagnostic procedures for rickettsial and chlamydial infections, 6th ed. American Public Health Association, Washington, DC.
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
“…BI-224436 (Boehringer-Ingelheim, Gilead), which has low nanomolar antiviral potency, LE = 0.33, and LLE = 11.5 (Table 1) (Fader et al., 2014; Fenwick et al., 2014). tBPQAs were found in an HTS designed to identify inhibitors of IN-catalyzed 30 processing of DNA; structural studies later…”
BackgroundInfluentialLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Block-And-Lock Strategies to Cure HIV Infection
Vansant, G., Bruggemans, A., Janssens, J., & Debyser, Z. (2020) · Viruses · doi:10.3390/v12010084 · Cited by 169
da Cunha, J., Maselli, L. M. F., Stern, A. C. B., Spada, C., & Bydlowski, S. P. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.56 · Cited by 171
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Vranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
“In any case LEDGIN treatment results in a steep dose-dependent inhibition of viral replication in cell culture, supporting their clinical development (Fader et al., 2014; Fenwick et al., 2014).”
BackgroundCellular and molecular mechanisms of HIV-1 integration targeting
Engelman, A., & Singh, P. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2772-5 · Cited by 115
“Other terms include NCINIs for non-catalytic site integrase inhibitors [183, 185, 187] and INLAIs for integrase-LEDGF allosteric inhibitors [188].”
BackgroundMethodHost factors for retroviral integration site selection
Debyser, Z., Christ, F., Rijck, J. D., & Gijsbers, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.001 · Cited by 104
LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)
Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.898753 · Cited by 83
“Second-generation INSTIs such as dolutegravir have a higher genetic barrier toward resistance, but close monitoring of Expert Opin.”
BackgroundInfluentialMultifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
“ALLINI and INSTI potencies are additive/synergistic (203, 206), and ALLINIs retain their potency in the face of clinically relevant INSTI resistance mutations (167, 170, 203).”
BackgroundStructural Basis for Inhibitor-Induced Aggregation of HIV Integrase
Gupta, K., Turkki, V., Sherrill-Mix, S., Hwang, Y., Eilers, G., Taylor, L., McDanal, C., Wang, P., Temelkoff, D., Nolte, R. T., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002584 · Cited by 68
Massari, S., Goracci, L., Desantis, J., & Tabarrini, O. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01474 · Cited by 63
Quercetin as an antiviral agent inhibits the Pseudorabies virus in vitro and in vivo
Sun, Y., Li, C., Li, Z., Shangguan, A., Jiang, J., Zeng, W., Zhang, S., & He, Q. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198556 · Cited by 53
Hu, S., Chen, J., Cao, J.-X., Zhang, S., Gu, S., & Chen, F.-E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106549 · Cited by 54
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 60
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
“…(ADME) and animal pharmacokinetic studies of quinoline- and pyridine-based inhibitors performed by Boehringer Ingelheim (BI) have indicated the superiority of the pyridine-based compounds as ‘a clinically viable starting point’ (Fader et al., 2016; Fader et al., 2014a; Fenwick et al., 2014).”
BackgroundGoing beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Elliott, J. L., & Kutluay, S. B. (2020) · Viruses · doi:10.3390/v12091005 · Cited by 51
Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Bonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
Park, T. E., Mohamed, A., Kalabalik, J., & Sharma, R. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1075393 · Cited by 42
“Thus, this new compound is expected to have different resistance profiles [85].”
BackgroundMaehigashi, T., Ahn, S., Kim, U.-I., Lindenberger, J. J., Oo, A., Koneru, P. C., Mahboubi, B., Engelman, A., Kvaratskhelia, M., Kim, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009671 · Cited by 40
Peese, K. M., Allard, C. W., Connolly, T., Johnson, B. L., Li, C., Patel, M., Sorensen, M. E., Walker, M. A., Meanwell, N. A., McAuliffe, B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01473 · Cited by 39
Multimodal Functionalities of HIV-1 Integrase
Engelman, A., & Kvaratskhelia, M. (2022) · Viruses · doi:10.3390/v14050926 · Cited by 41
“Substitutions that confer ALLINI resistance in cell culture generally occur at CCD-CCD binding interface residues [209,215,223,226,227,230,236], though CTD-proximal changes can also confer resistance [230].”
BackgroundZuo, X., Huo, Z., Kang, D., Wu, G., Zhou, Z., Liu, X., & Zhan, P. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1438410 · Cited by 39
“Unfortunately, the clinical development of 28 was halted without disclosing the reason, probably due to the enterohepatic recirculation-related PK issues [59,60].”
BackgroundDifferent Pathways Leading to Integrase Inhibitors Resistance
Thierry, E., Deprez, E., & Delelis, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02165 · Cited by 40
“…the full length protein, has been identified by several independent groups and consists in a specific endonucleolytic activity of IN onto a short ODN mimicking the palindromic sequence found at the LTR-LTR junction of 2-LTRc (Delelis et al., 2005, 2007; Shadrina et al., 2014; Zhang et al., 2014).”
BackgroundInfluentialDeng, N., Hoyte, A., Mansour, Y. E., Mohamed, M. S., Fuchs, J. R., Engelman, A. N., Kvaratskhelia, M., & Levy, R. (2016) · Protein Science · doi:10.1002/pro.2997 · Cited by 36
Zhang, D., Yan, H.-L., Xu, X., Xu, L., Yin, Z., Chang, S., & Luo, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1743282 · Cited by 37
GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture
Bruggemans, A., Vansant, G., Balakrishnan, M., Mitchell, M. L., Cai, R., Christ, F., & Debyser, Z. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-20 · Cited by 35
“between the two classes, and combination treatment even showed synergistic effects (37, 38).”
BackgroundExploring the Free-Energy Landscape and Thermodynamics of Protein-Protein Association
Tse, C., Wickstrom, L., Kvaratskhelia, M., Gallicchio, E., Levy, R. M., & Deng, N. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.08.005 · Cited by 34
“1) was taken from the structure of the aberrant tetramer containing the ALLINI BI224436 described in the previous report (4).”
MethodInfluentialHIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors
Spearman, P. W. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150902102143 · Cited by 37
Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs
Fader, L. D., Bailey, M., Beaulieu, E., Bilodeau, F., Bonneau, P., Bousquet, Y., Carson, R. J., Chabot, C., Coulombe, R., Duan, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00194 · Cited by 26
Self-citationvan Bel, N., van der Velden, Y., Bonnard, D., Le Rouzic, E., Das, A. T., Benarous, R., & Berkhout, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103552 · Cited by 23
“Because of the rapid emergence of cross-resistance among INSTI drugs, new IN-inhibitors were designed that prevent this IN-LEDGF/p75 interaction: LEDGINs [8], tBPQAs [9], INLAIs [10], NCINIs [9,11,12] or, as we will call them, ALLINIs [13].”
BackgroundDevelopment of Protein–Protein Interaction Inhibitors for the Treatment of Infectious Diseases
Voter, A. F., & Keck, J. L. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.07.005 · Cited by 24
“During in vitro analysis, BI 224436 demonstrated antiviral activity against a range of viruses resistant to other therapeutics and had a promising animal pharmacokinetic profile, which prompted the initiation of a phase I clinical trial in 2010 (Fenwick et al., 2014).”
Cruz, J., Wickstrom, L., Yang, D., Gallicchio, E., & Deng, N. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b01119 · Cited by 26
Amadori, C., van der Velden, Y. U., Bonnard, D., Orlov, I., van Bel, N., Le Rouzic, E., Miralles, L., Brias, J., Chevreuil, F., Spehner, D., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0373-2 · Cited by 22
Jentsch, N. G., Hume, J. D., Crull, E. B., Beauti, S. M., Pham, A. H., Pigza, J. A., Kessl, J. J., & Donahue, M. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.229 · Cited by 24
Investigational HIV integrase inhibitors in phase I and phase II clinical trials
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1378643 · Cited by 24
“The positive results justified the study of the drug in phase 1 clinical trials [34].”
BackgroundCao, J., Liu, Y., Zhou, M., Dong, S., Hou, Y., Jia, X., Lan, X., Zhang, Y., Guo, J., Xiao, G., et al. (2022) · Viruses · doi:10.3390/v14020353 · Cited by 20
“The volumes of statistically significant synergy were evaluated, and a combination volume (CV) of >25 μM2 % was interpreted as evidence of synergy and >100 μM2 % as strong synergy [35].”
MethodHan, Y.-S., Xiao, W., Quashie, P. K., Mésplède, T., Xu, H., Deprez, E., Delelis, O., Pu, J., Sun, H., & Wainberg, M. A. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.001 · Cited by 20
Gupta, K., Allen, A., Giraldo, C., Eilers, G., Sharp, R., Hwang, Y., Murali, H., Cruz, K., Janmey, P., Bushman, F., et al. (2021) · Structure · doi:10.1016/j.str.2020.12.001 · Cited by 19
Debyser, Z., Bruggemans, A., Belle, S. V., Janssens, J., & Christ, F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-0267-2_4 · Cited by 18
Y-box-binding protein 1 supports the early and late steps of HIV replication
Weydert, C., van Heertum, B., Dirix, L., Houwer, S. D., Wit, F. D., Mast, J., Husson, S. J., Busschots, K., König, R., Gijsbers, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200080 · Cited by 19
Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
Bonnard, D., Rouzic, E. L., Singer, M. R., Yu, Z., Strat, F. L., Batisse, C., Batisse, J., Amadori, C., Chasset, S., Pye, V. E., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-23 · Cited by 17
“July 2023 Volume 67 Issue 7 10.1128/aac.00462-23 15 Cocrystallization of BDM-2 with isolated HIV-1 IN CCD. Expression and purification of the HIV-1 IN CCD F185K (50-212) were performed as previously described (12) and used for crystallization.”
BackgroundMethodInfluentialImplications of Fragment-Based Drug Discovery in Tuberculosis and HIV
Mallakuntla, M. K., Togre, N. S., Santos, D. B., & Tiwari, S. (2022) · Pharmaceuticals · doi:10.3390/ph15111415 · Cited by 17
Targeting Virus-host Interactions of HIV Replication
Weydert, C., Rijck, J. D., Christ, F., & Debyser, Z. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150901115106 · Cited by 17
Zhang, F.-H., Debnath, B., Xu, Z.-L., Yang, L.-M., Song, L.-R., Zheng, Y., Neamati, N., & Long, Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.045 · Cited by 16
Newly approved integrase inhibitors for clinical treatment of AIDS
Gu, W.-G. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.09.013 · Cited by 17
Dinh, T., Tber, Z., Rey, J. S., Mengshetti, S., Annamalai, A. S., Haney, R., Briganti, L., Amblard, F., Fuchs, J. R., Cherepanov, P., et al. (2024) · mBio · doi:10.1128/mbio.00465-24 · Cited by 14
“The A128T change is the most frequently detected resistance mutation against different ALLINI chemotypes (1, 5, 6, 14, 34).”
Burlein, C., Wang, C., Xu, M., Bhatt, T., Stahlhut, M. W., Ou, Y., Adam, G. C., Heath, J., Klein, D. J., Sanders, J. M., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00550 · Cited by 14
Ohata, Y., Tomonaga, M., Watanabe, Y., Tomura, K., Kimura, K., Akaki, T., Adachi, K., Kodama, E. N., Matsuzaki, Y., & Hayashi, H. (2022) · Journal of Virology · doi:10.1128/jvi.01843-21 · Cited by 14
“8%) are polymorphisms that were reported to emerge as a result of in vitro resistance selection with NCINIs (24, 25, 35, 40, 42).”
BackgroundMethodInfluentialNaidu, B. N., Patel, M., McAuliffe, B. V., Ding, B., Cianci, C., Simmermacher, J., Jenkins, S., Parker, D. D., Sivaprakasam, P., Khan, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02169 · Cited by 14
Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia
Čermáková, K., Weydert, C., Christ, F., Rijck, J. D., & Debyser, Z. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.005 · Cited by 14
Sayyed, S. K., Quraishi, M., Jobby, R., Rameshkumar, N., Kayalvizhi, N., Krishnan, M., & Sonawane, T. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03461-8 · Cited by 15
Rashamuse, T. J., Fish, M. Q., Coyanis, E. M., & Bode, M. L. (2021) · Molecules · doi:10.3390/molecules26206203 · Cited by 13
“The X-ray crystal structure of HIV-1 IN dimer (PDB code: 4NYF) in complex with the small molecule, BI 224436 (2), was used for a better understanding of binding interactions of the tested ligands [27].”
BackgroundSun, L., Gao, P., Zhan, P., & Liu, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1210127 · Cited by 13
“Especially, compound 22 (BI 224436) was the first allosteric HIV IN inhibitor to advance into a phase Ia clinical trial (but further trials with BI-224436 was halted) [21,22].”
BackgroundDiscovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor
Parcella, K. E., Wang, T., Eastman, K. J., Zhang, Z., Yin, Z., Patel, M., Tu, Y., Zheng, B. Z., Walker, M. A., Saulnier, M. G., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00115 · Cited by 12
Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition
Vanangamudi, M., Nair, P. C., Maida Engels, S. E., Senthilkumar, P., & Namasivayam, V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-0267-2_3 · Cited by 13
Optimizing the Multimerization Properties of Quinoline-Based Allosteric HIV-1 Integrase Inhibitors
Sun, J., & Kessl, J. J. (2024) · Viruses · doi:10.3390/v16020200 · Cited by 12
The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario
Renzi, G., Carta, F., & Supuran, C. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512187 · Cited by 12
Eilers, G., Gupta, K., Allen, A., Montermoso, S., Murali, H., Sharp, R. B., Hwang, Y., Bushman, F. D., & Duyne, G. D. V. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011097 · Cited by 11
“In serial passage resistance studies with BI-224436, the mutations A128T and A128N arise(37,60), which would be predicted to clash with the Tyr226 side-chain in addition to the R4 substituent noted earlier, resulting in xxx.”
InfluentialHIV-1 Integrase Inhibition: Looking at Cofactor Interactions
Christ, F., & Debyser, Z. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.162 · Cited by 10
Shinde, P. B., Bhowmick, S., Alfantoukh, E., Patil, P. C., Wabaidur, S. M., Chikhale, R. V., & Islam, M. A. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107319 · Cited by 10
A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor
Nakamura, T., Nakamura, T., Amano, M., Miyakawa, T., Yamagata, Y., Matsuoka, M., & Nakata, H. (2020) · Journal of Virology · doi:10.1128/jvi.00486-20 · Cited by 9
“RAL, EVG, and DTG were purchased from Selleck Chemicals, and NCINI-4 (BI224436) was obtained from MedChemExpress LLC. Data availability.”
BackgroundMethodInfluentialIdentification and Optimization of a Novel HIV-1 Integrase Inhibitor
Adu‐Ampratwum, D., Pan, Y., Koneru, P. C., Antwi, J., Hoyte, A. C., Kessl, J. J., Griffin, P. R., Kvaratskhelia, M., Fuchs, J. R., & Larue, R. C. (2022) · ACS Omega · doi:10.1021/acsomega.1c06378 · Cited by 8
Parcella, K. E., Patel, M., Tu, Y., Eastman, K. J., Peese, K. M., Gillis, E. P., Belema, M., Dicker, I. B., McAuliffe, B. V., Ding, B., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116833 · Cited by 8
HIV-1 Integrase Drug Discovery Comes of Age
Demeulemeester, J., Maeyer, M. D., & Debyser, Z. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_33 · Cited by 9
New designs for HIV-1 integrase inhibitors: a patent review (2018-present)
Taoda, Y., Sugiyama, S., & Seki, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2178300 · Cited by 7
Ortiz-Hernández, G. L., Sanchez-Hernández, E. S., Ochoa, P. T., & Casiano, C. A. (2024) · Cancers · doi:10.3390/cancers16233957 · Cited by 7
Yin, Z., Yan, H.-L., Pan, Y., Zhang, D., & Yan, X. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2081869 · Cited by 9
“0 nM [21], validating that the assay was effective and suitable for drug screening applications.”
MethodInfluentialDawei, Z., He, H.-Q., Mengmeng, L., Meng, Z., & Shunxing, G. (2016) · Scientific Reports · doi:10.1038/srep33477 · Cited by 8
Pre‐clinical pharmacological profile of QF‐036, a potent HIV‐1 maturation inhibitor
Zhao, L. M., He, H., Ou‐Yang, T., Liu, D., Jiang, C., Yang, H., Wang, P., Xie, N., & Yan, S. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13504 · Cited by 7
Aknin, C., Smith, E. A., Marchand, C., Andréola, M., Pommier, Y. G., & Métifiot, M. (2019) · Molecules · doi:10.3390/molecules24203675 · Cited by 7
“From a more pharmacological point of view, inhibitors of the IN-LEDGF interaction have been shown to exhibit an additive effect with current active site inhibitors [24].”
BackgroundComplex of HIV-1 Integrase with Cellular Ku Protein: Interaction Interface and Search for Inhibitors
Ilgova, E., Galkin, S., Khrenova, M. G., Serebryakova, M. V., Gottikh, M., & Anisenko, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062908 · Cited by 7
“interaction, a family of allosteric inhibitors was recently developed and characterized, first called LEDGINs [12,13], and then ALLINIs for allosteric IN inhibitors [14], NCINIs for non-catalytic IN inhibitors [15,16], MINIs for multimerization integrase inhibitors [17], or INLAIs for integrase-LEDGF allosteric inhibi…”
BackgroundMontermoso, S., Eilers, G., Allen, A., Sharp, R., Hwang, Y., Bushman, F. D., Gupta, K., & Duyne, G. D. V. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169224 · Cited by 5
“In serial viral passage experiments conducted in the presence of ALLINIs, many resistance substitutions have been reported [13,22,23] that vary with chemotype and are cross-resistant, consistent with similar passage experiments against other molecules in this drug class.”
Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor
Park, K. H., Kim, M., Bae, S. E., Lee, H. J., Kim, K.-C., Choi, B. S., & Kim, Y. B. (2021) · Virology Journal · doi:10.1186/s12985-020-01476-x · Cited by 6
Expeditious Synthesis of a Potent Allosteric HIV-1 Integrase Inhibitor GSK3839919A
Bobko, M. A., Elward, J. M., Naidu, B. N., Nieves‐Quinones, Y., Reiher, C. A., Su, Q., Sun, L. D., Woodard, J., Xie, S., Yang, W., et al. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00343 · Cited by 5
Gu, W.-G., Liu, B., & Yuan, J. F. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.959020 · Cited by 4
“BI 224436 is advanced into Phase 1 clinical trials based on its excellent biological performance [34].”
BackgroundNew Antiretrovirals for HIV and Antivirals for HBV
Lazerwith, S. E., Siegel, D. S., McFadden, R. M., Mish, M., & Tse, W. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12407-2 · Cited by 6
Block-and-Lock Approaches for HIV Cure: Mechanistic Insights, Challenges, and Emerging Role of CPSF6
Tolomeo, M., & Cascio, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083496 · Cited by 3
NMR spectroscopy can help accelerate antiviral drug discovery programs
LaPlante, S. R., Coric, P., Bouaziz, S., & França, T. C. C. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105297 · Cited by 4
“6 Although this presented some workflow limitations, fruitful discoveries also resulted [24-26].”
BackgroundSelf-citationThe Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients
da Cunha, J., Maselli, L. M. F., Bydlowski, S. P., & Spada, C. (2015) · InTech eBooks · doi:10.5772/61061 · Cited by 3
“This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site [172, 173].”
BackgroundCiubotaru, M., Musat, M. G., Surleac, M. D., Ionita, E., Petrescu, A., Abele, E., & Abele, R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180406114405 · Cited by 3
Gordon, C. P., Dalton, N., Vandegraaff, N., Deadman, J. J., Rhodes, D. I., Coates, J. A. V., Pyne, S. G., Griffith, R., Bremner, J. B., & Keller, P. A. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.11.052 · Cited by 2
Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS
Liao, C., & Wang, Q. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00026-7 · Cited by 4
Adachi, K., Manabe, T., Yamasaki, T., Suma, A., Ogoshi, Y., Takahashi, A., Orita, T., Nomura, A., Adachi, T., Ohata, Y., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118526 · Cited by 1
Identification of specific phylogenetic properties of HIV-1 M and O integrases
Toccafondi, E. (2022) · theses.fr (ABES) · doi:10.70675/2facab6ezc20az472dz8350z9fb6e718e1d4 · Cited by 1
Amadori, C. (2016) · theses.fr (ABES) · doi:10.70675/2da75a32z2820z4ceaz8909zee47e88e36ee
“Celui-ci étant différent du site actif de l’enzyme ciblé par les inhibiteurs catalytiques de l’IN, les INLAIs possèdent une activité antirétrovirale lors de l’infection par des virus porteurs de mutations aux INSTIs [340,341,359].”
BackgroundInfluentialCeresola, E. R. (2019) · IrInSubria (University of Insubria)
Immune Cell Cross Talk in the Establishment of Human Immunodeficiency Virus-1 Latency
Rachel, G., Vembuli, H., Purushothaman, G. K. C., & Hanna, L. E. (2023) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0062
Research progress in small-molecule modulators of protein-protein interactions
Yang, B., & Qi, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0034
Carta, F., & Sechi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00006-1
Identification and evaluation of inhibitors targeting the HIV-1 integrase-LEDGF/p75 interaction
Harrison, A. T. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Caractérisation des voies d’échappement aux inhibiteurs d’intégrase du VIH-1
Thierry, E. (2015) · theses.fr (ABES) · doi:10.70675/602eaec1z5d9az4bb2za08dz10755e91efc2
HIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency
Bruggemans, A., Vansant, G., Pellaers, E., de Velde, P. V., Christ, F., & Debyser, Z. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01699-25
“Indeed, toxicology studies with BI 224,436 (tested in rats, monkeys, and dogs [32]) and STP0404 (tested in rats and dogs [43]) did not show urothelial vacuolation; hence, this toxicity is probably not a class effect.”
Targeting HIV-1 integrase: A review of options, challenges and future directions
Bourquin, R. A., & Schaeffer, P. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153092 · Cited by 1
Metadata
- Authors
- Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., Fader, L. D., Faucher, A.-M., Garneau, M., Jakalian, A., Kawai, S., Lamorte, L., LaPlante, S., Luo, L., Mason, S., Poupart, M.-A., Rioux, N., Schroeder, P., Simoneau, B., Tremblay, S., Tsantrizos, Y., Witvrouw, M., & Yoakim, C.
- Affiliations
- Boehringer Ingelheim (Canada) (CA)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-06
- Volume
- 58
- Issue
- 6
- Pages
- 3233-3244
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4068430
- OpenAlex
- W2131078522
- Cited by
- 99
- References
- 56
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 8 · 2014: 7
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase inhibitors, integrase strand transfer inhibitors, integrase resistance mutations, allosteric pocket, antiviral activity, drug resistance, combination therapy, pharmacokinetics, ADME properties, structure-based drug design
- MeSH terms
- Animals, Cloning, Molecular, DNA, Viral, Humans, Virus Replication, HIV-1, Caco-2 Cells, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Hepatocytes, Drug Resistance, Viral, Serum, Mice, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.